Mechanisms Underlying Metastatic Pancreatic Cancer

被引:6
|
作者
Pitarresi, Jason R. [1 ,2 ]
Rustgi, Anil K. [3 ]
机构
[1] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA
关键词
Pancreatic cancer; Epithelial-mesenchymal transition (EMT); Cellular plasticity; Metastasis; Metastatic organotropism; TO-MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; EPITHELIAL PLASTICITY; CELLS; EMT; PROGRESSION; EXPRESSION; KRAS(G12D); INHIBITOR; COOPERATE;
D O I
10.1007/978-3-030-22254-3_1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma is an overwhelming fatal disease that often presents with overt metastases and ultimately causes the majority of cancer-associated deaths. The mechanisms underlying the metastatic cascade are complex, and research in recent years has begun to provide insights into the underlying drivers of this phenomenon. It has become clear that cancer cells, in particular pancreatic cancer cells, possess properties of plasticity involving bidirectional transition between epithelial and mesenchymal identities. Furthermore, recent work has begun to establish that there are distinct hybrid states between purely epithelial and purely mesenchymal states that cancer cells may reside, in order to thrive at different stages of carcinogenesis. We discuss how this plasticity is important for different phases of the metastatic cascade, from delamination to colonization, and how different epithelial-mesenchymal states may affect metastatic organotropism. In this review, we summarize the current understanding of pancreatic cancer cell plasticity and metastasis, and highlight current model systems that can be used to study these phenomena.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 50 条
  • [41] Is metastatic pancreatic cancer an untargetable malignancy?
    Kourie, Hampig Raphael
    Gharios, Joseph
    Elkarak, Fadi
    Antoun, Joelle
    Ghosn, Marwan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 8 (03) : 297 - 304
  • [42] The hepatic metastatic niche in pancreatic cancer
    Schmid, M.
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2019, 100 (04) : A3 - A3
  • [43] Metastatic Pancreatic Cancer: Where Are We?
    Hernandez-Blanquisett, Abraham
    Quintero-Carreno, Valeria
    Martinez-Avila, Maria Cristina
    Porto, Maria
    Manzur-Barbur, Maria Carolina
    Buendia, Emiro
    ONCOLOGY REVIEWS, 2024, 17
  • [44] Systemic therapy for metastatic pancreatic cancer
    Zaiden, Robert
    Zhou, Louise
    Kim, George P.
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (06) : 653 - 658
  • [45] Cutaneous presentation of metastatic pancreatic cancer
    Abdelaziz, Mohammed
    Thorley, Daniel
    Ahmed, Waseem
    JOURNAL OF SURGICAL CASE REPORTS, 2022, 2022 (12):
  • [46] Recent advances in metastatic pancreatic cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S53 - S53
  • [47] Treatment of Patients with metastatic Pancreatic Cancer
    Wirth, Thomas
    Nitschmann, Sirka
    INNERE MEDIZIN, 2024,
  • [48] Laser immunotherapy for metastatic pancreatic cancer
    Zhou, Feifan
    BIOPHOTONICS AND IMMUNE RESPONSES XII, 2017, 10065
  • [49] Is metastatic pancreatic cancer an untargetable malignancy?
    Hampig Raphael Kourie
    Joseph Gharios
    Fadi Elkarak
    Joelle Antoun
    Marwan Ghosn
    World Journal of Gastrointestinal Oncology, 2016, (03) : 297 - 304
  • [50] Systemic Therapy for Metastatic Pancreatic Cancer
    Thomas J. Ettrich
    Thomas Seufferlein
    Current Treatment Options in Oncology, 2021, 22